#Israel #Tel Aviv #CBD Therapy #Cholesterol Management #CannaLean

CannaLean Biotechs' Positive Feasibility Study Outcomes

CannaLean Biotechs Ltd., a pioneering biotech firm in the clinical development of cannabis-derived therapies, recently shared exciting news regarding its first-in-human feasibility study for a novel drug aimed at addressing dyslipidemia. The study focused on evaluating the safety and biological activity of its patented cannabidiol–chitosan (CBD–CHT) formulation, specifically designed for patients suffering from high levels of LDL cholesterol, often referred to as bad cholesterol.

Conducted in partnership with Clalit Health Services, Israel's largest healthcare organization, the study leveraged a robust network of community clinics to facilitate clinical evaluations in real-world settings. This strategic alliance not only enriched the trial's execution but also highlighted the collaborative potential in advancing healthcare innovations.

Key Findings from the Study

The trial ramped up interest in CannaLean's proprietary formulation, termed CLC-01. The results from this feasibility study were encouraging:

• - Safety Profile: CLC-01 was generally well-received among participants. Notably, no serious adverse events were reported, with only mild and transient incidents occurring. This favorable safety profile supports ongoing clinical development and the potential for dose optimization.
• - Efficacy Signals: Over a 12-week treatment phase, participants noted a significant reduction in LDL cholesterol levels, with a 28% decrease observed by the end of the study as compared to the control group. Total cholesterol levels also exhibited a similar downward trend, affirming the formulation’s promise as an effective therapeutic option.

Addressing a Vital Health Concern

Dyslipidemia, affecting hundreds of millions globally, is a significant contributor to cardiovascular diseases and increased mortality rates. Although statins are commonly prescribed to manage cholesterol levels, many patients struggle to meet their targets or deal with adverse side effects. CannaLean's approach seeks to fill this gap in the market by offering a well-tolerated, scalable, second-line treatment alternative. This could dramatically improve health outcomes for individuals who either cannot tolerate existing treatments or are seeking additional options.

Regulatory Environment and Market Opportunities

The landscape surrounding cannabinoid-derived therapies is evolving rapidly, with recent regulatory shifts in the United States indicating a broader acceptance of such treatments. Significant progress in federal cannabis reclassification and public healthcare initiatives aimed at evaluating CBD applications are paving the way for more extensive and structured development pathways.

CannaLean is poised to take full advantage of these changes as it prepares to advance CLC-01 into a larger and more robust clinical trial program. This next phase will focus not only on efficacy but also on establishing a trajectory towards regulatory approval. Concurrently, the company is considering parallel wellness-oriented commercialization strategies that align with current health market trends.

Conclusion and Future Directions

Professor Moshe Mittelman, CannaLean's Chief Scientific Officer, remarked on the significance of these findings, stating, "These first-in-human results provide an important validation of our platform." The company’s innovations are set to progress into larger clinical studies that will further explore the benefits of CLC-01. The ultimate goal remains clear: to create a safe, effective pharmaceutical product that contributes positively to metabolic health.

For more information on CannaLean Biotechs and their ongoing projects, visit CannaLeanBiotechs.